The reverse split is a mechanical recapitalization to meet Nasdaq's minimum bid price requirement. Monitor the next 10-Q for the post-split share count and cash position. The inclusion of active shelf/S-1 registration statements suggests potential future equity issuance is still available, which could create overhang.
Price Chart
Executive Summary
Silo Pharma filed a Certificate of Change effecting a 1-for-15 reverse stock split, effective June 2, 2026, to regain compliance with Nasdaq listing requirements. The authorized common shares were reduced proportionately from 100M to ~6.67M, and the split was automatically incorporated into the company's active registration statements.
Key Facts
- Filed on June 1, 2026, effective June 2, 2026 at 4:01 p.m. ET; began trading on split-adjusted basis June 3, 2026.
- 1-for-15 reverse stock split of common stock, par value $0.0001 per share.
- Authorized common shares reduced from 100,000,000 to 6,666,667.
- CUSIP changed to 82711P 300; trading symbol SILO unchanged.
- No fractional shares issued; fractional holdings were rounded up to the next whole share.
- Proportionate adjustments made to outstanding stock options, warrants, and shares reserved under equity plans.
- The company has active S-1 (Nos. 333-280855, 333-291129) and S-3 (No. 333-276658) registration statements; the reverse split was incorporated by reference to adjust share amounts under Rule 416(b).
Financial Impact
No immediate financial impact; mechanical capital structure adjustment. Reduces share count and authorized shares by 93%.
Risk Factors
- Post-split share price may not sustain above $1.00, risking delisting.
- Registered shares under S-1 and S-3 could lead to dilutive offerings.
- Low market cap ($6M) makes the stock volatile post-split.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-064804 |
| Document: ea029311101ex3-1.htm | 0001213900-26-064804 |
| Document: 0001213900-26-064804-index-headers.html | 0001213900-26-064804 |
| Document: 0001213900-26-064804-index.html | 0001213900-26-064804 |
| Document: 0001213900-26-064804.txt | 0001213900-26-064804 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $1.20 | awaiting T+60 | — | $1.29 (+7.50%) |
Oct 2, 2026 25d ago | 8-K | $1.49 | awaiting T+60 | — | $1.29 (−13.42%) |
Sep 18, 2026 5w ago | Press Release | $1.84 | awaiting T+60 | — | $1.29 (−29.89%) |
Aug 7, 2026 11w ago | EFFECT | $3.74 | awaiting T+60 | — | $1.29 (−65.46%) |
Jul 14, 2026 15w ago | Press Release | $5.13 $1.44 | ▼ −71.93% | ▼ −75.31% | $1.29 (−74.85%) |
Jun 30, 2026 17w ago | DEFA14A | $6.21 $1.77 | ▲ +71.50% | ▲ +75.06% | $1.29 (+79.23%) |
Jun 3, 2026 20w ago | 8-K | $6.11 $2.54 | ▼ −58.43% | ▼ −60.31% | $1.29 (−78.89%) |
Jun 1, 2026 21w ago | 8-K | $4.99 $2.59 | ▼ −48.09% | ▼ −49.32% | $1.29 (−74.14%) |
Apr 29, 2026 25w ago | Press Release | $6.74 $4.47 | ▼ −33.63% | ▼ −37.74% | $1.29 (−80.85%) |
Apr 22, 2026 26w ago | Press Release | $7.11 $4.70 | ▼ −33.90% | ▼ −38.91% | $1.29 (−81.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers